Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAFNE: Afatinib + trastuzumab with taxane-anthracycline chemotherapy as neoadjuvant therapy in HER2-positive breast cancer
2011-004704-38Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and trastuzumab in breast cancer, sponsored by GBG Forschungs. Primary endpoint: Pathological complete response of breast and lymph nodes. Started Feb 2012; status: completed.
02
Drugs
afatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-004704-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004704-38.